MICHAEL ZAFRANI: Open Payments
NPI 1982780128 · AICA, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,485 in 190 payments from 11 companies in 2025. Trend: 2023 $5,398 · 2024 $4,372 · 2025 $5,485
Food & beverage: $5,391Education: $94
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 32 | $1,510 |
| Neurocrine BioSciences, Inc. | 34 | $858 |
| ABBVIE INC. | 31 | $816 |
| Otsuka America Pharmaceutical, Inc. | 21 | $583 |
| Lundbeck LLC | 17 | $473 |
| E.R. Squibb & Sons, L.L.C. | 16 | $424 |
| Vanda Pharmaceuticals Inc. | 14 | $262 |
| Janssen Pharmaceuticals, Inc | 9 | $224 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $182 |
| Axsome Therapeutics, Inc. | 5 | $126 |
Products named: UZEDY, INGREZZA, VRAYLAR, REXULTI, AUSTEDO XR, COBENFY, ABILIFY MAINTENA, FANAPT.
Industry payments across HI — which companies pay providers there.
